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Abstract
Background: Hypertension is a complex disease with many contributory genetic and
environmental factors. We aimed to identify common targets for therapy by gene expression
profiling of a resistance artery taken from animals representing two different models of
hypertension. We studied gene expression and morphology of a saphenous artery branch in
normotensive WKY rats, spontaneously hypertensive rats (SHR) and adrenocorticotropic
hormone (ACTH)-induced hypertensive rats.
Results: Differential remodeling of arteries occurred in SHR and ACTH-treated rats, involving
changes in both smooth muscle and endothelium. Increased expression of smooth muscle cell
growth promoters and decreased expression of growth suppressors confirmed smooth muscle cell
proliferation in SHR but not in ACTH. Differential gene expression between arteries from the two
hypertensive models extended to the renin-angiotensin system, MAP kinase pathways,
mitochondrial activity, lipid metabolism, extracellular matrix and calcium handling. In contrast,
arteries from both hypertensive models exhibited significant increases in caveolin-1 expression and
decreases in the regulators of G-protein signalling, Rgs2 and Rgs5. Increased protein expression of
caveolin-1 and increased incidence of caveolae was found in both smooth muscle and endothelial
cells of arteries from both hypertensive models.
Conclusion: We conclude that the majority of differences in gene expression found in the
saphenous artery taken from rats with two different forms of hypertension reflect distinctive
morphological and physiological alterations. However, changes in common to caveolin-1
expression and G protein signalling, through attenuation of Rgs2 and Rgs5, may contribute to
hypertension through augmentation of vasoconstrictor pathways and provide potential targets for
common drug development.
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Hypertension is a complex condition with many contrib-
utory genetic and environmental factors [1], which have
constrained identification of the genes, biochemical path-
ways and pathophysiological processes that accompany
its development. Hypertension is a critical risk factor for
stroke, renal failure and cardiovascular disease and has
been associated with a range of well recognized complica-
tions, including congestive heart failure, left ventricular
hypertrophy, and atherosclerosis, and with more subtle
structural and functional changes to target organs and tis-
sues occurring as a consequence of enhanced salt sensitiv-
ity [2], enhanced angiotensin II sensitivity [3] and
structural modifications to the arterial wall [4,5]. Genetic
factors are thought to partly account for structural changes
by directly influencing the quantity, density and organiza-
tion of the extracellular matrix and also indirectly through
association with risk factors such as age, gender, blood
pressure, total and high-density lipoprotein cholesterol,
smoking and diabetes [6].
A variety of both genetic, such as the spontaneously
hypertensive rat (SHR), and nongenetic, such as glucocor-
ticoid-induced hypertension, animal models of hyperten-
sion have been developed [7]. Administration of
adrenocorticotropic hormone (ACTH) to rats provides a
quick and reproducible means of inducing hypertension
by stimulating the adrenal production of corticosterone
[8]. ACTH-induced hypertension was originally thought
to involve altered kidney function and loss of control of
blood volume [9] but is now known to involve disruption
of the nitric oxide synthase (NOS) pathway at various
points, affecting NO bioavailability, oxidative stress and
function of the endothelium [10,11]. The genetically
hypertensive SHR is a renin-angiotensin system-depend-
ent model of hypertension that also exhibits oxidative
stress and disrupted endothelial NOS (eNOS) activity
[12,13]. Such convergence in effectors holds the promise
of some overlap in causative factors.
Hypertension is generally characterized by remodeling of
arteries, such as thickening of the media and intima,
reduced lumen diameter and reduced distensibility [14].
Endothelial dysfunction is also a characteristic of hyper-
tension and alterations to endothelial morphology and
density have been described [15-17]. Resistance vessels
have a primary role in autoregulation of the blood supply
to the vascular bed and changes to their structure and
function are crucial to the onset of target organ damage
[4]. Angiotensin II has a prominent role in affecting resist-
ance vessels as a pro-inflammatory stimulator of signaling
pathways promoting vascular growth, remodeling and
oxidative stress [18,19]. Both hypertrophic and eutrophic
remodeling have been documented in arteries of SHR,
perhaps related to the size of the vessel and intraluminal
pressures experienced [20-23]. Whether similar changes
to resistance vessels accompany ACTH-induced hyperten-
sion is not known. Microarray expression profiling offers
a means of studying the modifications to global gene
expression that accompany these events [24] and hence
may provide novel insights into potential targets for com-
mon therapeutic intervention. The aim of the present
study was therefore to compare gene expression and mor-
phology of a resistance artery from adult normotensive
Wistar-Kyoto (WKY) rats, SHR and ACTH-induced hyper-
tensive rats; the latter two as representatives of renin-angi-
otensin-dependent and steroid-dependent hypertension,
respectively. Although the majority of genetic changes dif-
fered between the two hypertensive models, changes in
common were found to caveolin-1 expression and the reg-
ulators of G protein signalling, Rgs2 and Rgs5.
Results
Blood pressure of SHR and ACTH-treated rats was signifi-
cantly elevated over that of age-matched WKY rats (Table
1).
Anatomy of saphenous arteries from normotensive and 
hypertensive rats
The internal vessel circumference of arteries taken from
both ACTH-treated rats and SHR showed a trend towards
a decrease, compared with WKY, although only saphen-
ous arteries from SHR exhibited hypertrophy of the
smooth muscle cell layers (Figure 1, Table 1). In the
endothelium, there was a significant reduction in the area
of endothelial cells in SHR, while area was significantly
increased during ACTH-treatment (Table 1). There was no
significant difference between experimental groups in the
density of myoendothelial gap junctions per endothelial
cell, which were rarely encountered in either WKY, SHR or
ACTH-treated rats (Table 1).
Assessment of RNA degradation
The extent of RNA degradation was assessed by comparing
the MAS5-derived 3'/5' and 3'/M' (middle) ratios of the
Table 1: Morphological characteristics of primary branches of the 
saphenous artery
Parameter WKY ACTH SHR
Systolic BP (mmHg) 123 ± 5 (5) 146 ± 3* (10) 187 ± 4* (9)
Circumference (μm) 745 ± 36 (4) 628 ± 51 (7) 610 ± 22 (6)
Mean SMC layers 7.2 ± 0.1 (4) 6.7 ± 0.4 (7) 8.7 ± 0.4* (5)
Area of EC (μm2) 392 ± 9 (5) 438 ± 13* (6) 279 ± 4* (3)
MEGJs/EC 0.1 ± 0.08 (4) 0.06 ± 0.04 (4) 0.03 ± 0.03 (3)
Mean ± SEM; number of animals in parentheses. *p < 0.05 compared to 
WKY. Myoendothelial gap junctions (MEGJs) are expressed per 
endothelial cell (EC). Measurement of EC area from 150 cells (WKY), 
76 cells (ACTH) and 45 cells (SHR). SMC = smooth muscle cell. Data 
for WKY from reference [49].Page 2 of 17
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(Table 2). The 3'/5' ratios for GAPDH for all 12 samples
were in the range 3–7, which is acceptable for doubly-
amplified RNA, while the 3'/M' ratios for GAPDH were
less than 2. Similar data were found for the 3'/5' and 3'/M
ratios for hexokinase although some of the ratios tended
to be greater than those for GAPDH, perhaps due to the
longer hexokinase transcripts (3653 bp, versus 1268 bp
for GAPDH).
Statistical analysis of microarrays
Of the 15,878 probesets on each array, 9098 were present
in all replicates of at least one experimental group
(Affymetrix MAS5 Statistical Algorithm) and considered
for further analysis. One-way ANOVA on each of the 9098
probesets showed significant differences in expression of
870 genes amongst the 3 experimental groups (F-test p
value cutoff of 0.02) or 136 genes (p value cutoff of
0.001). The data discussed in this publication have been
deposited in NCBIs Gene Expression Omnibus (GEO) at
the following website [25] and are accessible through
GEO Series accession number GSE8051.
The 50 most significant probesets found by ANOVA were
superimposed on a GE-biplot of the 9098 probesets
present in all arrays of at least one experimental group
(Figure 2A). The locations of the probesets are shown as
red asterisks with the 50 most significant genes indicated.
The locations of the arrays are connected to the centre of
the plot and labelled by their respective names. Figure 2A
shows that the replicates within each experimental group
are clustered together relative to the other groups, indicat-
ing consistency in measurement. In this genome-wide
view the three experimental groups, WKY, ACTH and SHR
groups are well separated, providing evidence of overall
transcriptional differences between the groups.
The genes separating from the dense group in the centre of
Figure 2A have relatively high variance. The labelled genes
have a statistically significant difference in their means in
the three groups. Generally the statistically significant
Table 2: MAS5-derived 3'/5' and 3'/M' (in brackets) ratios of 
housekeeping genes.
Array name RAT-GAPDH RAT-HEXOKINASE
SHR1 3.57 (1.38) 2.55 (3.05)
SHR2 3.79 (1.32) 1.63 (1.80)
SHR3 5.16 (1.55) 3.39 (3.42)
WKY1 5.35 (1.89) 2.01 (4.23)
WKY2 5.99 (1.76) 1.61 (2.15)
WKY3b 4.91 (1.66) 8.79 (0.69)
ACTH1 3.96 (1.64) 3.56 (3.02)
ACTH2 4.52 (1.72) 4.48 (0.72)
ACTH3 3.67 (1.64) 12.54 (1.08)
Typical morphology of saphenous arteries from 16 week normotensive and hypertensive animalsFigure 1
Typical morphology of saphenous arteries from 16 
week normotensive and hypertensive animals. Fewer 
smooth muscle layers were present in vessels from normo-
tensive WKY (A) and hypertensive ACTH (B) than in SHR 
(C). Bar, 10 μm.
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Clustering of arrays visualised by two different methodsFigure 2
Clustering of arrays visualised by two different methods. A. GE-biplot of the 9098 probesets (red asterisks) with the 
first 50 (1 = most significant), as ranked by ANOVA, indicated. The position of each array is shown as a label joined by a dotted 
line to the origin. B. A heat map (white: up-regulated; red: down-regulated) using hierarchical clustering with complete linkage 
for the columns only. The rank order of the p-values, gene names and Affymetrix IDs are included on the right and correspond 
to the numbering in A.
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BMC Genomics 2007, 8:404 http://www.biomedcentral.com/1471-2164/8/404genes on the left of the plot have relatively low expres-
sions in SHR but high and approximately equal expres-
sion in WKY and ACTH. Those statistically significant
genes on the right of the centre have relatively high expres-
sion values in SHR and low and approximately equal
expression in WKY and ACTH. These patterns in gene
expression are the dominant genome-wide patterns. How-
ever there are a number of genes which are relatively
highly expressed in ACTH (eg. 9, 31, 48) compared to
WKY and SHR.
The heat map of the 50 most significant genes in Figure 2B
shows that the arrays cluster according to experimental
groups but the experimental groups differ substantially, in
agreement with clustering in the GE-biplot.
Validation of microarray results by quantitative PCR
Eleven out of 12 genes (6 in SHR, 6 in ACTH) which
showed significant variation from WKY in the microarrays
were validated by quantitative PCR (Table 3). The one var-
iant gene (adenylate cyclase3) was significantly different
in the SHR by microarray, but found not to differ from
WKY by quantitative PCR. In contrast, four of 14 genes (7
in SHR, 7 in ACTH) which did not show any significant
difference in expression in the microarrays relative to
WKY, were found to be significantly different to WKY
when assayed using quantitative PCR (Table 3). Three of
these genes were found to be decreased in expression rel-
ative to WKY and one gene increased in expression (Table
3). These data concord with a recent analysis of microar-
ray data which showed a high false-negative rate, or low
sensitivity, especially in the case of genes showing small
fold-changes [26].
Differentially and co-ordinately expressed genes between 
the two models of hypertension
Genes that were identified as significantly altered in
expression by ANOVA in eight multiple comparisons of
SHR and ACTH relative to WKY are given in Additional
Files 1, 2, 3, 4, 5, 6, 7, 8: Tables S1–8. Genes identified in
six dual comparisons of either SHR or ACTH with WKY
are given in Additional Files 9, 10, 11, 12, 13, 14: Tables
S9–14. Gene names, gene descriptions, biological func-
tion, Affymetrix IDs, accession numbers, expression levels
and p-values are provided. The biological association net-
works of selected genes for each model of hypertension
are shown in Figure 3A,B.
Table 4 summarises the changes in genes which relate to a
range of processes or pathways which could impact on
blood pressure regulation. The majority of changes reflect
Table 3: Validation of microarray data using quantitative PCR
Affymetrix 
ID
Accession No. Gene name Fold-change of 
signal Microarray
Fold-change of 
signal qPCR
Validate
SHR ACTH SHR ACTH SHR ACTH
1387128_at NM_130779.1 Adcy3, adenylate cyclase 3 0.70* 0.67* 1.01 0.37* No Yes
1370131_at NM_031556.1 Cav1, caveolin 1 2.88* 2.51* 10.76* 2.53* Yes Yes
1367600_at NM_022531.1
BC061872
Des, desmin 0.38* 0.87 0.58* 0.76 Yes Yes
1371166_at NM_021838.2
AJ011116.1
NOS3, eNOS, endothelial nitric oxide synthase 1.26 1.00 0.89 0.72 Yes Yes
1373499_at BF287008
U77829
Gas5, growth arrest specific 5 0.77* 1.59* 0.18* 1.55* Yes Yes
1386881_at NM_012588.1 Igfbp3, insulin-like growth factor binding protein 3 1.22 3.38* 0.87 2.07* Yes Yes
1375857_at AW917760
XM_220031
Myof, myoferlin 1.64* 0.90 2.52* 1.01 Yes Yes
1371776_at AA819268
NM_013005
Pik3r1, PI3 kinase regulatory subunit polypeptide 1 13.21* 1.12 2.30* 2.04* Yes No
1368144_at 
1387074_at
AF321837.1
AY043246.1
Rgs2, regulator of G-protein signaling 2 1.12 
0.84
0.46* 
0.52*
0.63* 0.19* No Yes
1370228_at X77158 Tf, transferrin 1.44 3.40* 0.65* 1.80* No Yes
1370023_at NM_021654.1
M76532
Gja4, connexin37, Cx37 0.96 0.82 0.79 1.06 Yes Yes
1368473_at NM_019280.1
BC070935
M83092
Gja5, connexin40, Cx40 1.09 0.95 0.73 1.36 Yes Yes
1372002_at AI411352
NM_012567
Gja1, connexin43, Cx43 1.27 0.96 0.36* 1.07 No Yes
* significantly different from WKY.
Two microarray values for Rgs2 represent 2 different Affymetrix probesets.Page 5 of 17
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Biological association networks of interactions between selected differentially expressed genes in SHR (A) and ACTH-induced m dels of hypertension (B)F gure 3
Biological association networks of interactions between selected differentially expressed genes in SHR (A) and 
ACTH-induced models of hypertension (B). Probesets selected for input had an overall ANOVA p-value ≤ 0.02 and a t-
test value ≤ 0.015 for the contrasts between SHR and WKY (483 probesets) or ACTH and WKY (377 probesets), respec-
tively. Genes are color-coded according to the log2-fold change of the mean value of gene expression in SHR or ACTH com-
pared to WKY. Red indicates up-regulated expression compared to WKY, green down-regulation. Blue shape surrounds 
coordinate changes in the two models. Oval = protein; oval with cutout = kinase; oval with flat base = transcription factor; pol-
ygon with flat base = phosphatase; rectangle with small base = receptor; diamond = ligand; blue square = expression; grey cir-
cle = direct regulation; purple circle = binding; green circle = promoter binding; khaki hexagon = protein modification.
A
B
SHR
ACTH
BMC Genomics 2007, 8:404 http://www.biomedcentral.com/1471-2164/8/404the specific morphological and physiological alterations
occurring in the two different types of hypertension.
Saphenous arteries from SHR showed upregulation of
genes associated with renin-angiotensin signalling
through MAP kinase ERK1/2 pathway and were character-
ised by upregulation of growth promoters and down reg-
ulation of growth suppressors (Table 4). In contrast,
arteries from ACTH-treated animals showed upregulation
of the p38MAP kinase pathway, diverse effects on growth
promoters and suppressors (Table 4) and prominent
involvement of the transcription factor Jun (Figure 3B).
Differences were also found in expression of genes
involved in mitochondrial activity, lipid metabolism, cal-
cium handling, adenylate cyclase, ion transport and pro-
tein kinase C. In contrast, coordinate upregulation in both
forms of hypertension was found for caveolin-1 and its
interaction and modification by the membrane-associ-
ated tyrosine kinase Fyn (Figure 3, blue shape), and coor-
dinate downregulation of Rgs2 and Rgs5, the regulators of
G protein signalling (Tables 3, 4).
Distribution of caveolin-1 and caveolae in saphenous 
arteries of normotensive and hypertensive rats
Expression of caveolin-1 was found in the membranes of
both the endothelial and smooth muscle cells of saphen-
ous arteries of WKY rats (Figure 4A, D, arrows). Expression
varied both within and between cells in the endothelium
(Figure 4A) and also throughout the muscle layers (Figure
4D). An increase in caveolin-1 expression was found in
both endothelial cells and smooth muscle cells of arteries
taken from both SHR and ACTH, compared to WKY rats
(Figure 4B, C, compare 4A; Figure 4E, F compare 4D).
Table 4: Comparison of changes in gene expression in functional pathways
Process or Pathway SHR ACTH
Renin-angiotensin system ↑Ace1, ↑Atip1
MAP kinase ERK1/2 ↑Phb, ↑Raf1 ↓Phb
MAP kinase p38 ↓Dusp1, ↓Map4k2, ↓Map2k3 ↑Dusp1
G-protein signalling ↑Gnb2, ↑Rac1
↓Rgs2, ↓Rgs5
↑Gnb2, ↑Rac1
↓Rgs2, ↓Rgs5
cAMP ↓Adcy3, ↓Akap12 ↑Akap12
↓Adcy2, ↓Adcy3
PKC ↑Pkcη
↓Pkcι
Nitric oxide ↑Caveolin-1 ↑Caveolin-1
Endothelins ↑EdnrB
Reactive oxygen stress ↑Rac1
↓Rtp801, ↓Egln3
↑Rac1
↓Rtp801
Calcium handling ↑Anxa3, ↑Anxa4, ↑Anxa7, ↑Casq2, ↑Efhc1, ↑S100A16
↓Anxa8, ↓Anxa11, ↓Nucb2
↑Anxa4, ↑Anxa7, ↑Efhc1
Ion transport ↑Atp1b1, ↑Kcnmb1
↓Clcn3e, ↓Sat, ↓Ttyh1
↓Cacnb2, ↓Clcn3e, ↓Ttyh1
Mitochondrial activity ↑Aco2, ↑Mrpl3, ↑Mrpl48, ↑Mrps18b, ↑Ndufs2
↓Frda, ↓Mrpl4, ↓Pdk2, ↓Ssbp1, ↓Timm22
↓Ndufs3, ↓Pdk2
Growth promoting ↑Minpp1, ↑P-Rex1, ↑Myof, ↑Ceacam1, ↑Ctgf, ↑Vegfr, 
↑Vegfr1
↓Aebp1, ↓Igfbp2, ↓Klf9, ↓Bmp4, ↓Igfbp5
↑Bmp4, ↑Ceacam1, ↑Ctgf, ↑Vegfr
↓Aebp1, ↓Igfbp2, ↓Igfbp5, ↓Klf9, ↓p311, ↓Pdgrfl
Growth suppressing ↓Basp1, ↓Bmp6, ↓Cst3, ↓Gas5, ↓Kank, ↓Stk11ip, ↓SerpinB5, 
↓Smurf2, ↓Smoc1, ↓Tem7, ↓Tnmd
↑Gas5, ↑Igfbp3, ↑Wisp-2
↓Basp1, ↓Tem7, ↓Tnmd
Insulin & glucose transport ↑Sord, ↑Glud1, ↑Enpp1, ↑Gsk3β
↓Bpgm, ↓Pcsk1, ↓Sort1
↑Sord, ↑Glud1
↓Bpgm, ↓Pcsk1, ↓Sort1, ↓Gsk3β
Lipid metabolism ↑Phb
↓Decr1, ↓Acsl3, ↓Mafb
↑Acsl1, ↑Hmgcs2
↓Lpl, ↓Phb
Extracellular matrix ↑Icap1, ↑Fyn
↓Col1A2, ↓Icam2, ↓Lox, ↓Loxl, ↓Sdc1, ↓Slit3
↑Fyn
↓Col1A1, ↓Col1A2, ↓Col3A1, ↓Col4A1, ↓Col4A2, 
↓Col5A1, ↓Col8A1, ↓Col12A1, ↓Col15A1, 
↓Col18A1, ↓Lox, ↓Loxl, ↓Sdc1, ↓SerpinH1, ↓Slit3
Smooth muscle-related 
genes
↑Acta1, ↑CaMkIId, ↑Ca3, ↑Fgl2, ↑Ldha, ↑Myof1, ↑Raf1, 
↑Pcmt1
↓Aebp1, ↓Cst3, ↓Des, ↓Gas5
↑Acta1, ↑Ca3, ↑Cnn3, ↑Gas5, ↑Igfbp3
↓Aebp1, ↓CaMkIId, ↓Gadd45, ↓p311
Endothelium-related genes ↑Cxcl12, ↑Ecmn, ↑Gp38, ↑Hmox2, ↑Mmn1,↑Thbd
↓Recs1, ↓Tem7, ↓vWF
↑Gp38, ↑Mmn1, ↑Thbd
↓Angpt2, ↓Tem7
↑ = expression increased compared with WKY.
↓ = expression decreased compared with WKY.
See Additional Files: Tables S1–S14 for details.Page 7 of 17
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BMC Genomics 2007, 8:404 http://www.biomedcentral.com/1471-2164/8/404Paired confocal images of either whole mounts or sections
were taken with the same voltage and pinhole settings so
that comparisons could be made of the extent of staining.
Preincubation of the antibody with the immunogen abol-
ished staining in endothelial and smooth muscle cells
(Figure 4G).
At the ultrastructural level, caveolae were found along the
membranes of both endothelial and smooth muscle cells
of arteries from WKY rats (Figure 5A, B), although there
were fewer on the abluminal than luminal endothelial
surface. While the incidence of caveolae was increased in
both cell types in the SHR (Figure 5C, D), the differential
distribution in the endothelium was still apparent. In
Expression of caveolin-1 in saphenous arteriesFigure 4
Expression of caveolin-1 in saphenous arteries. Whole mount preparations (A, B, C) and longitudinal sections (D, E, F) 
through the vessel wall show increased expression of caveolin-1 in both endothelial cells (EC: A-C) and in smooth muscle cells 
(SMC: D-F) of saphenous arteries taken from SHR (B, E) and ACTH (C, F), compared to WKY (A, D). Arrows indicate staining 
delineating the membranes of smooth muscle cells (D-F). Preincubation of the antibody with the immunogen eliminated stain-
ing in both endothelium and smooth muscle (G). Calibration bars represent 25 μm.
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BMC Genomics 2007, 8:404 http://www.biomedcentral.com/1471-2164/8/404arteries from ACTH rats, a differential distribution in the
endothelium was less obvious as caveolae were found in
abundance on both sides of the endothelial cells (Figure
5E). Caveolae were also more abundant throughout the
muscle layers of ACTH-treated rats, than of WKY rats (Fig-
ure 5F, compare 5B).
Caveolae in endothelium and smooth muscle of saphenous arteriesFigure 5
Caveolae in endothelium and smooth muscle of saphenous arteries. Caveolae (cav; arrows) were found along the 
membranes of both endothelial (EC) and smooth muscle cells (SMC) of saphenous arteries of WKY, (A, B), SHR (C, D) and 
ACTH-treated rats (E, F). In the SHR and ACTH-treated rats, the incidence of caveolae was increased in both cell types (C, E 
compare A; D, F compare B). IEL, internal elastic lamina. Bar, 5 μm.
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Comparative gene expression profiling of a resistance
artery taken from rats with either renin-angiotensin-
dependent or glucocorticoid-induced hypertension has
identified over 800 genes showing significant changes.
Statistical analysis of the microarrays showed consistency
in gene expression amongst the replicates within each
experimental group but evidence of substantial transcrip-
tional differences between the two hypertensive models
and the normotensive controls. The majority of these dif-
ferences reflected differential vascular remodeling, as con-
firmed by our anatomical studies, as well as activation of
specific intracellular pathways. Nevertheless, arteries from
both models exhibited significantly increased expression
of caveolin-1, which binds a number of important signal-
ling molecules including endothelial nitric oxide synthase
[27], and significantly decreased expression of Rgs2 and
Rgs5, which terminate the signalling of the G proteins Gq
and Gi/o [28]. Together these common effects would be
expected to elevate blood pressure through augmentation
of vasoconstrictor mechanisms.
Saphenous arteries from SHRs were characterised by
hypertrophic remodeling, in contrast to the arteries from
the ACTH rats in which no alterations were found in the
number of smooth muscle cell layers. Similar changes
have been described in other arteries of SHR [20,22,23],
typical of remodeling of similarly sized resistance vessels
during angiotensin II-induced hypertension [19]. The
absence of hypertrophy in the saphenous artery of ACTH-
treated rats suggests that inward eutrophic remodeling
[14] may be more common to this form of hypertension,
perhaps related to the lower blood pressures experienced
in comparison with those of the SHR. In the endothelium
of SHR arteries, there was a significant reduction in the
area of endothelial cells, consistent with changes observed
in other muscular arteries of SHR [29-31]. Surprisingly,
the area of endothelial cells was increased during ACTH-
treatment resulting in a decrease in overall endothelial cell
numbers. Changes in gene expression were consistent
with cell proliferation in angiotensin II-dependent hyper-
tension but not in glucocorticoid-induced hypertension.
Thus, expression of growth promoters was upregulated
and growth inhibitors suppressed in SHR arteries, while
effects on both growth promoters and inhibitors were
more diverse in the ACTH arteries. A lack of change in
myoendothelial gap junctions suggests that these struc-
tures are not involved in the remodeling processes in
saphenous arteries in either form of hypertension.
A large number of other genetic differences in the arteries
from the two hypertensive models emerged from the
study. These related to lipid metabolism, mitochondrial
activity, calcium handling, ion transport, the adenylate
cyclase pathway and protein kinase C. Not surprisingly,
saphenous arteries from SHR showed upregulation of
genes consistent with renin-angiotensin hypertension,
and angiotensin II signaling pathways through Raf and
MEK1/2 [19]. Upregulation of growth promoters and
down regulation of growth suppressors as found in the
SHR samples would be expected to stimulate cell growth
and proliferation, mobilise intracellular Ca2+ and reactive
oxygen species [18,32]. In contrast, the saphenous arteries
from ACTH-treated animals showed upregulation of the
p38MAP kinase pathway which is involved in inflamma-
tion and apoptosis, as well as growth and differentiation
[33], accentuating mechanistic differences between the
two models of hypertension. While alterations to the
extracellular matrix were found in both hypertensive
models, substantial changes involving multiple collagen
genes were found predominantly in the ACTH model.
Such changes have been linked with hypertension [34]
and could impact on cytoskeletal signalling through
integrin receptors.
Downstream mechanisms underlying smooth muscle
contraction and calcium sensitization also varied between
the two hypertensive models. Calcium/calmodulin-
dependent protein kinase II (CaMkII) has an important
role in regulating smooth muscle contractility by inhibit-
ing myosin light chain kinase (MLCK) and the phosphor-
ylation of myosin light chain [35]. In SHR, upregulation
of CaMkII may shift smooth muscle contraction toward
Rho-dependent mechanisms and decreased phosphatase
activity. In contrast, in ACTH, CaMkII was downregulated
suggesting that smooth muscle contraction could be more
influenced by MLCK, in addition to Rho-dependent
mechanisms.
In the face of these substantial differences in gene expres-
sion between the two hypertensive models, we found
coordinate upregulation in gene expression of caveolin-1
and increased caveolin-1 protein in both endothelial and
smooth muscle cells. Our ultrastructural observations of
increased incidence of caveolae in these sites provides
strong confirmation of the immunohistochemical find-
ings since caveolae are absent in caveolin-1 knockout
mice [36]. While some of the genetic changes in SHR rel-
ative to WKY might have arisen through decades of isola-
tion from the parent WKY strain following inbreeding,
coordinate changes in gene expression between the SHR
and the ACTH-treated WKY rats cannot be attributed to
such a cause. Caveolae are now recognized as important
sites for colocalisation of signaling molecules, including
receptor tyrosine kinases, G-protein-coupled receptors
and G-proteins, and hence are critical for vascular func-
tion [37]. The inactivation of eNOS through binding to
caveolin-1 is the best characterized function for caveolae
in endothelial cells [37], highlighting their crucial role in
vascular homeostasis. Alterations to caveolae in smoothPage 10 of 17
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studies of idiopathic pulmonary arterial hypertension in
humans have concluded that increased smooth muscle
expression of caveolin-1 contributes to the pathophysiol-
ogy of the disease through increased capacitative calcium
entry [38]. Whether upregulation of caveolin-1 in smooth
muscle cells and in endothelial cells could serve to induce
hypertension warrants further investigation.
In contrast to caveolin-1, the G protein regulators, Rgs2
and Rgs5, were coordinately downregulated in both SHR
and ACTH saphenous arteries. These molecules terminate
G protein signalling through Gq and Gi/o by activating
the GTPase activity of the Gα subunit. Downregulation
thus potentiates the effect of vasoconstrictors like
endothelin and angiotensin II [39]. A role in blood pres-
sure regulation has been demonstrated for Rgs2, since
knockout mice are severely hypertensive [40]. Activation
of Rgs2 occurs in resistance and conduit arteries through
binding of protein kinase G, the downstream mediator of
nitric oxide action [40,41]. Interestingly, Rgs2 was also
decreased in aortic smooth muscle during L-NAME-
induced hypertension [42]. Upregulation of caveolin-1
and decreased eNOS function may therefore play a role in
the downregulation of Rgs2.
Less is known about a role in blood pressure regulation
for Rgs5, which has been described as a marker of arterial
but not venous smooth muscle cells [43] and is downreg-
ulated during proliferation to form atherosclerotic
plaques [44]. In contrast, upregulation of Rgs5 has been
reported during neovascularisation of tumours [45]. Rgs5
has also been identified in endothelial cells of cerebral
capillaries where it was downregulated in stroke-prone
SHR compared to SHR [46]. Our results demonstrating
downregulation in arteries from both SHR and ACTH rats
would suggest a role in hypertension rather than prolifer-
ation since smooth muscle hypertrophy was not a feature
of the ACTH model.
Conclusion
Study of changes in gene expression in two different mod-
els of hypertension have highlighted numerous differ-
ences which can be linked to variation in the form of
vascular remodeling and the unique signalling pathways
affecting contractility and cell growth. In contrast, we have
identified common changes to upstream targets crucial for
the alteration in the balance between vasoconstriction
and vasodilation as occurs in hypertension. Common
increases in expression of caveolin-1 are likely to increase
vasoconstriction through direct effects on calcium influx
in smooth muscle cells and indirect inhibitory effects on
eNOS in endothelial cells. Decreases in Rgs2 and Rgs5 will
augment these effects by prolonging the actions of Gq and
Gi/o and their downstream vasoconstrictor pathways.
Further studies examining the functional implications of
these data and aimed at reversing these gene changes dur-
ing the different forms of hypertension are needed to
determine whether these molecules could be considered
as therapeutic drug targets.
Methods
Sixteen-week-old male WKY and age-matched SHR were
used. These rats were originally from stock derived from
the National Institutes of Health, Bethesda, MD. A group
of 12-week-old male WKY rats was administered ACTH
(0.2 mg/kg/day) subcutaneously for 4 weeks. Systolic
blood pressure was measured using tail-cuff plethysmog-
raphy. All experiments were approved by the Australian
National University Animal Experimentation Ethics Com-
mittee under guidelines of the National Health and Med-
ical Research Council of Australia.
All analyses were made on the first lateral branch of the
saphenous artery. This vessel was defined as a resistance
vessel due to its small diameter (<250 μm), since feed
arteries and the microcirculation contribute to blood pres-
sure regulation in rats [47].
Electron microscopy
Ultrastructural studies were conducted on a minimum of
3 arteries each from a different rat, as previously described
[48,49]. WKY, ACTH and SHR rats were anaesthetized
(i.p., 44 and 8 mg/kg, ketamine and xylazine, respec-
tively) and perfused via the left ventricle with 0.1% BSA,
0.1% NaNO3 and 10 U/ml heparin and fixed with 1%
paraformaldehyde, 3% glutaraldehyde in 0.1 M sodium
cacodylate buffer, with 10 mM betaine, 0.2 mM CaCl and
0.15 M sucrose, pH 7.4, using standard procedures [48].
The first lateral branch of the saphenous artery diverging
towards the knee was removed and processed for electron
microscopy [48,49]. Serial transverse sections (~100 nm
thick) totalling ~5 μm of vessel length were cut from each
vessel using 3–4 animals/experimental group. Myoen-
dothelial gap junctions connecting the endothelium to
the inner layer of smooth muscle were counted and pho-
tographed at ×3,500 to ×60,000 on a Phillips 7100 trans-
mission electron microscope. Vessel circumference at the
internal elastic lamina, the number of smooth muscle cell
layers and endothelial cell areas were determined for each
vessel as previously described [48,49]. Statistical signifi-
cance was tested using one-way ANOVA followed by Stu-
dent's t-test with Bonferroni correction for multiple
groups. A p-value < 0.05 was taken as significant. The inci-
dence of caveolae was assessed in montages of the vessel
wall using a minimum of 3 arteries, each from a different
rat, for each rat group.Page 11 of 17
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Rats were anaesthetized as above and perfused with 2%
paraformaldehyde in 0.1 M sodium phosphate buffer. The
lateral branch of the saphenous artery was removed from
both hind legs. Arteries were processed either as whole
mounts or were sectioned at 10 μm. Preparations were
incubated overnight at room temperature with rabbit
antibodies against human caveolin-1 (Santa Cruz; 1:200
for whole mounts, 1:1000 for sections) followed by 1
hour in Cy3 conjugated anti-rabbit IgG (1:100, Jackson
Immunoresearch Laboratories). For whole mounts, opti-
cal confocal series were taken throughout the thickness of
the endothelium and recombined to a single image. For
tissue sections, optical confocal series were taken through-
out the section thickness and recombined to a single
image. All images were collected using the same pinhole
and voltage settings so that comparisons could be made of
the intensity and extent of staining in arteries from the dif-
ferent rat groups (3 animals/group). Specificity of the
staining was tested by preincubation of the antibody with
a ten-fold excess of the immunogen.
Extraction of total RNA
Rats were anesthetized with ether and killed by decapita-
tion. The saphenous artery branch was removed, stripped
of extraneous material and stored in RNAlater (Ambion).
Three different samples were prepared for each experi-
mental group, i.e. WKY, SHR and ACTH. The choice of
three biological replicates was based on the constraints of
limited availability of mRNA and the high costs of micro-
array experiments. This is a common choice in the micro-
array literature [50]. Each sample, which comprised
arteries from 2–3 animals, was snap frozen in liquid nitro-
gen and processed using the RNeasy Micro Kit (Qiagen),
including 20 min DNAse treatment. Concentrations of
RNA were measured using a NanoDrop ND-1000 spectro-
photometer (NanoDrop Technologies). RNA quality was
monitored using RNA 6000 Pico LabChip kit (Agilent
2100 Bioanalyzer). RNA integrity numbers for the 9 sam-
ples ranged from 6.4 to 8.1 [51].
Preparation of cRNA and hybridization on microarrays
Sample preparation followed the Affymetrix GeneChip
Eukaryotic Small Sample Target Labeling Assay Version II
available at the website [52]. After first round amplifica-
tion, the yields of unlabeled cRNA ranged from 2.8–7.8
μg. Following the second round amplification, 600 ng of
unlabeled cRNA was used for the second round of cDNA
synthesis. Double-stranded cDNA was synthesized using
oligo(dT) 24-anchored T7 primer, Superscript III (Invitro-
gen) and 100 ng total RNA for the first strand followed by
DNA polymerase I and T4 DNA polymerase for the second
strand. The double-stranded cDNA was precipitated with
ethanol, air-dried and used as template for the first round
of in vitro transcription of cRNA with MEGAscript enzyme
mix (Ambion) at 37°C for 7 h. The cRNA was purified
(RNeasy, Qiagen) and used as template for the second
round of double-stranded cDNA synthesis with random
primers (Invitrogen). The double-stranded cDNA product
of second round synthesis was purified by ethanol precip-
itation and used as template for the second round of in
vitro transcription and labeling of cRNA, using the ENZO
BioArray HighYield RNA Transcript Labeling kit (Affyme-
trix) according to the manufacturer's protocol. The yields
of labelled cRNA ranged from 58–193.8 μg. All compo-
nents were mixed, incubated at 37°C for 7 h, and the
biotin-labeled cRNA (1 μg for each sample) was purified
(RNeasy, Qiagen) and fragmented prior to hybridisation
to Affymetrix GeneChip RAE230A arrays. Hybridization,
washing and staining followed the Affymetrix GeneChip
Expression Analysis protocols.
Microarray data analysis
Probeset signal values were calculated using the Statistical
Algorithm in the Affymetrix MAS5 software. Raw data
were normalised by scaling the global mean method to a
TGT value of 150. Quality of all arrays was assessed using
MAS5 quality control metrics and software procedures
available in R/Bioconductor (Bioconductor version 1.8.0
[53]) and at the following website [54]. Based on these
metrics, the quality of all arrays was considered to be sat-
isfactory (see Additional file 15).
One-way ANOVA was carried out on the log2 transformed
MAS5 signal values for each of the 9098 probesets which
were present in all replicates of at least one experimental
group (Affymetrix MAS5 Statistical Algorithm). Differ-
ences between experimental groups were examined using
t-tests (post-hoc contrasts).
GE-biplot and Heat Map
An ordination method, the GE-biplot [55], based on the
singular value decomposition of the data matrix of scaled
log2 signal values, was obtained using an R function avail-
able at the website [54]. The GE-biplot is an unsupervised
visualisation tool that facilitates the detection of subsets
of genes associated with subsets of microarrays. It pro-
vides a genome-wide view of the data, showing genes and
microarrays simultaneously. Co-regulated (correlated)
genes are located close to each other, with genes having
reversed response profiles (negatively correlated) being
located on the opposite side of the plot. Genes lying fur-
ther from the centre have higher variance. Genes which lie
close to, or lie in the direction of, a group of samples are
relatively upregulated in that group compared with other
samples, while those lying in the opposite direction are
relatively down-regulated in that group. In a GE-biplot,
arrays that have approximately the same relative values of
gene expression across probesets cluster together. Further
details are described elsewhere [55].Page 12 of 17
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significant probesets as evaluated by one way ANOVA was
constructed [56]. Hierarchical clustering with complete
linkage was used to order the arrays in the columns of the
heat map and the rank order of the p-values from the
ANOVA was used to order the columns.
Validation of microarray analysis by quantitative PCR
Quantitative PCR was used to determine the copy num-
bers of mRNA for 13 genes in the WKY, SHR, and ACTH
samples (n = 3 for each). Details of the genes, primers and
product sizes are given in Table 5. Nine of the genes were
selected on the basis that their expression was signifi-
cantly altered in either SHR or ACTH and that they were
of biological interest to the processes involved in hyper-
tension. The three vascular connexins and eNOS,
although unaltered in the microarrays, were chosen
because of their significance to vascular function and
potential involvement in hypertension [57]. Validation of
the microarray data was considered to be a significant (p
< 0.05) change in normalised PCR copy number in the
same direction, or lack of a change in normalised PCR
copy number which corresponded to that found in the
microarray data.
Messenger RNA of all 9 saphenous artery samples was
reverse transcribed to cDNA (42°C 1 h, 50°C 1 h, 90°C
10 min) using oligo dT (500 ng.μl-1, Invitrogen) primers
and Superscript II (200 U.μl-1, Invitrogen). For every sam-
ple, control reactions from which either reverse tran-
scriptase or RNA was omitted were run in parallel. Each 25
μl PCR reaction mixture contained 1 μl of each primer
(final concentration 800 nM), 2 μl of 12.5 mM dNTPs, 3
μl of 25 mM MgCl2, 0.125 μl of AmpliTaq Gold (5 U. μl-
1), 2.5 μl of 10× SYBR Green buffer (SYBR Green Core Rea-
gents kit, Applied Biosystems), 10.375 μl H2O and 5 μl of
template containing either 10 ng of cDNA or diluted plas-
mid DNA containing the relevant cloned PCR product. All
samples were diluted in water containing tRNA (2 ng. μl-
1). All reactions were performed in duplicate (ABI Prism
7700 Sequence Detection System, ACRF Biomolecular
Resource Facility) at 95°C for 10 min, and 40 cycles of 20
sec at 95°C, 20 sec at 65°C, 45 sec at 72°C. Every experi-
ment included duplicate control reactions and the expres-
sion of all genes was determined in every sample. The
integrity of each PCR reaction was checked using dissoci-
ation curve analysis after every reaction.
For each gene, the mRNA concentration was determined
by comparing the fluorescent signal at threshold (equal to
Table 5: Real-time PCR primers for validation of microarray data.
Affymetrix Probeset ID Gene Product size (bp) Primers Forward Reverse
1387128_at Adcy3: adenylate cyclase 3 148 agcacctatatggcagcttctgga
taagcgtgtccttcatggctagtg
1370131_at Cav1: caveolin 1 150 gcttcaccaccttcactgtgacaa
ggaagctcttgatgcacggtacaa
1367600_at Des: desmin 164 gatcaaccttccgatccagacctt
gcacttcatgttgttgctgtgtgg
1371166_at NOS3: endothelial nitric oxide 154 tctggcaagaccgattacacgaca
synthase, eNOS gtgaggacttgtccaaacactcca
1386881_at Igfbp3: insulin-like growth factor- 167 tggaaacaccactgagtctgagga
binding protein 3 agtcaactttgtagcgctggctgt
1373499_at Gas5: growth arrest-specific 5 152 ccacctgattcaaactccaccatc
tctgtgatgggacatctggtggaa
1375857_at Myof: myoferlin 105 cgctgccgaactatttatccatga
cagacgtatgtgaggcgagagttc
1371776_at Pik3r1: phosphatidylinositol 3- 146 ggcgaagtcaaacattgcgtcatc
kinase regulatory subunit polypeptide 1 gtgacattgagggagtcattgtgc
1387074_at Rgs2: regulator of G-protein 151 ggtgtacagcctgatggagaacaa
signaling 2 tgggagacagaatggaatgtcctc
1370228_at Tf: transferrin 140 cgaacggaaagaacactgctgcat
gaccacaacatggtttggagcttg
1372002_at Gja1: connexin43 Cx43 306 gagatgcacctgaagcagattgaa
gatgttcaaagcgagagacaccaa
1368473_at Gja5: connexin40 Cx40 236 ggaaagaggtgaacgggaagatt
cacagccatcataaagacaatgaa
1370023_at Gja4: connexin37 Cx37 131 agctctgcatccaagaagcagta
agttgtctctcaagtgcctttga
- 18S rRNA GenBank acc. no. 110 ccagtagcatatgcttgtctcaa
X01117 cgaccaaaggaaccataactgattPage 13 of 17
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standard curve using serial dilutions of a known concen-
tration of purified plasmid DNA containing the relevant
cloned and sequenced PCR product. Sequences were
obtained using an ABI 3730 sequencer (ACRF Biomolecu-
lar Resource Facility, JCSMR, ANU). The concentration of
each mRNA was normalized by determining 18S rRNA
concentration, using primers complementary to a region
of the 5' end of the molecule and a standard curve using
serial dilutions of plasmid DNA containing the cloned
fragment of the 18S rRNA gene [29]. Results were ana-
lyzed for statistical significance (p < 0.05) using ANOVA
and Student's t-test.
Direct interactions between selected genes
To examine differences in the major pathways affected in
SHR and ACTH-induced hypertension, genes that were
identified by t-tests as significantly altered in expression in
SHR or ACTH compared with WKY (at the 0.015 level)
and that were significant in ANOVA at the 0.02 level, were
imported into a demonstration version of PathwayStudio
4.0 (Ariadne Genomics, Rockville, MD). This software
contains the proprietary ResNet 3.0 database of functional
relationships between genes, proteins and small mole-
cules automatically extracted from PubMed and scientific
journals using the MedScan natural language processing
software. Functional links between genes and proteins
were also investigated and cross checked using publicly
available gene and genome databases: Online Mendelian
Inheritance in Man (OMIM) and Genomic Biology and
software provided by NCBI [58], and the protein database
Human Protein Reference Database (HPRD; [59]) and
software [60].
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